

EXPLORATION OF THE SERUM METABOLIC DETERMINANTS OF MAMMOGRAPHY DENSITY, AS A RISK FACTOR FOR BREAST CANCER, IN WOMEN SCREENING IN A REFERENCE HOSPITAL IN BOGOTÁ, 2021

Andrea D. Hernández¹, Lizeth Leon², Ariadna Velasquez³, Jose Bacca³, Andres Felipe Patiño¹, Gabriela Lopez¹, Juliana Ramirez¹, Harold Mena¹, Ana Maria Pedraza¹, Mónica P. Cala², Alejandro Ondo-Mendez¹

¹ Clinical Research Group, School of Medicine and Health Sciences, Universidad Del Rosario, Bogota, Colombia.

² MetCore - Metabolomic Core Facility, Vice-Presidency for Research, Universidad de los Andes, Bogotá D.C., Colombia

³ Magister of Epidemiology, School of Medicine and Health Sciences, Universidad Del Rosario, Universidad CES, Colombia

INTRODUCTION

Breast cancer (BC)

It is the most common type of cancer, with more than 2.2 million cases in 2020. It accounted for 24% of all cancers diagnosed in women. Around 685 thousand women died as a result of this disease (1)

Mammographic density (MD)

It's an important risk factor for CS (2,3). It has been documented that the risk of women with high breast density is 4 to 6 times higher than that of women with low density (4)

Today, the most widely used method in clinical practice is the Breast Imaging Reporting and Data System (BI-RADS) density score.

has the potential to improve the quality of risk prediction models, however discriminatory accuracy remains limited at the individual level

Serum metabolic differences according to the percentage of mammographic density could represent an innovative and useful risk identification tool in clinical practice.




Figure 1. Midlateral oblique mammographic views depicting the 4 BI-RADS density categories: (A) Almost entirely fat (BI-RADS density 1) (B) Scattered fibroglandular densities (BI-RADS density 2) (C) Heterogeneously dense (BI-RADS density 3) (D) Extremely dense (BI-RADS density 4). BI-RADS = Breast Imaging Data and Reporting System.

OBJECTIVE

To explore the serum metabolic determinants of mammographic density as a risk factor for breast cancer, in women screened at a reference hospital in Bogotá, in the year 2021

METHODOLOGY

Study population

Women screened in the breast unit of the Clinica Colombia, in Bogotá, 2021

Mammography density classification:
• Low risk (LR): < 25%
• Moderate risk (MR): 26-50%
• High risk (HR): > 50%

Serum sample preparation and metabolite extraction

GC-MC

Quality control of metabolomic analyses

Data processing and analysis

Metabolite identification

Biological interpretation

Take anthropometric measurements and clinical variables

The metabolite extracts were derivatized using a two-step protocol: i) Methoxylation with O-Methoxyamine in pyridine (15 mg/mL, 70°C, 1 h) followed by ii) Silylation with BSTFA with 1% TMCS (70 °C, 1 h).

The derivatized samples were analyzed in a Agilent Technologies 7200 gas chromatograph coupled to a mass spectrometer with gas detector Quadrupole and High Resolution Time of Flight (GC-QTOF).

The deconvolution and identification of the metabolites was made using the Agilent program MassHunter Unknowns Analysis and the Fiehn and NIST libraries.

To determine the differences between the metabolic profiles, the groups under study and select the statistically significant metabolites, analysis was carried out univariate and multivariate unsupervised and supervised statistics.

RESULTS

n=60

Low risk: 28
Moderate risk: 16
High risk: 16

The significant demographic and clinical variables between the risk groups were: age $p(<0.001)$, sociodemographic stratum $p(0.025)$, visceral fat level $p(0.013)$, and hormonal status $p(0.001)$



Characterization
Age 59 ± 4 years,
BMI 27.8 ± 3 kg/m²
Low risk:
Age 56 ± 6 years,
BMI 26 ± 5 kg/m²
Moderate risk:
Age 52 ± 3 years, BMI 26 ± 5 kg/m²
High risk:


Correlation analysis
Age: $r = -0.84$
Degree of obesity: $r = -0.76$
Visceral fat level: $r = -0.79$
BMI: $r = -0.75$

In the analysis of metabolic pathways, a total of 19 pathways were detected. However, the metabolic pathway with a significant relationship, even after the FDR correction analysis, was the biosynthesis pathway of phenylalanine, tyrosine and tryptophan with significant p-value of FDR


Multivariate analysis

GM-GC/MS-QTOF

GM-GC/MS-QTOF




A.



B.

GM-GC/MS-QTOF



C.

Figure 2. A. Quality control of metabolomic analyses PCA B. Supervised analysis, partial least squares discriminant analysis (PLS-DA) C. Supervised analysis, orthogonal partial least squares regression (OPLS-DA) LR vs HR

Univariate analysis

Name ↓	AUC ↓	T-tests ↓	Log ₂ FC ↓
Xylitol	0.96296	7.3319E-7	-0.50256
Azelaic acid	0.84491	0.0010325	-1.0279
Alpha Ketoglutaric acid	0.8287	2.7923E-4	-0.45977
Glycerol monostearate	0.82639	3.0332E-4	0.45322
D-Arabinose	0.81481	0.00927	-1.0894
L-Tyrosine	0.81481	9.3073E-4	-0.59912
L-Threonine acid	0.7963	9.3083E-4	-0.36204
Erythriol	0.78935	5.9481E-4	-0.38395
N-acetyl-D-mannosamine	0.78704	0.0025343	-0.32856
1-Monopalmitin	0.77546	0.0036462	0.41754
Glycerol	0.77315	0.0019045	-0.70909
Hippuric acid	0.76852	0.027026	-0.87262

Figure 3. Discrimination and prediction capacity of metabolites to discriminate between groups LR vs HR

Bendinelli et al. described an inverse association of tyrosine with CS cases with high DM (OR 0.59, 95%CI 0.42–0.82, p value 0.002), highlighting that in models adjusted for confounding variables, only tyrosine continued to have an inverse association with CS cases with high MD (OR 0.51, 95%CI 0.27–0.94, p value 0.03)

127 metabolites identified, only 12 were significant after FDR corrections

Lucie Lecuyer et al. describe that high levels of glycerol are associated with a higher risk of developing breast cancer during the 13 years of follow-up, with an AUC of 0.69, 95% CI for the difference in AUC (0-0.6) $p(0.04)$.

FUNCTIONAL GROUPS




Figure 4. Functional group distribution of significant metabolites

Metabolite Sets Enrichment Overview




Figure 5. Analysis of metabolic pathways organized by enrichment pathway scores

CONCLUSIONS

- The significant differentiating metabolites of the risk groups are mainly involved in the pentose phosphate pathway, biosynthesis of phenylalanine, tyrosine and tryptophan, previously reported in the literature.
- Finding a relationship between the different metabolic profiles with the risk classification by mammographic density will make it possible to open other more specific investigations in the field of metabolomics, considering the identification of a plasmatic marker that will improve the efficacy of the tests currently used test for risk detection and screening of this disease in Colombia and the world.

References:

- Breast cancer [Internet]. [citado 30 de septiembre de 2021]. Disponible en: <https://www.who.int/news-room/fact-sheets/detail/breast-cancer>
- Ravner M, Harkness EF, Foden P, Wilson M, Gadde S, Beetles U, et al. Reader performance in visual assessment of breast density using visual analogue scales: Are some readers more predictive of breast cancer? 1 de marzo de 2018;10577:10577-0.
- Vilmun BM, Veiborg I, Lyng E, Lillholm M, Nielsen M, Nielsen MB, et al. Impact of adding breast density to breast cancer risk models: A systematic review. Eur J Radiol. junio de 2020;127:109019.
- McCormack VA, dos Santos Silva I. Breast density and parenchymal patterns as markers of breast cancer risk: a meta-analysis. Cancer Epidemiol Biomark Prev Publ Am Assoc Cancer Res Cosponsored Am Soc Prev Oncol. junio de 2006;15(6):1159-69
- Rice MS, Rosner BA, Tamimi RM. Percent mammographic density prediction: development of a model in the nurses' health studies. Cancer Causes Control. 1 de julio de 2017;28(7):677-84.